Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e31824cc46b
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget
Oncology
2017English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2008English

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

Scientific Reports
Multidisciplinary
2019English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology
Forensic MedicinePathology
2008English

Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

PCN10 Targeted Therapy (TT) for First Line Treatment of Advanced Renal Cell Carcinoma (RCC): An Indirect Comparison Meta-Analysis (ICMA)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy